$4.01
0.01[0.25%]
At close: Apr 29
$4.01
0[0.00%]
After Hours: 7:34AM EDT
SAB Biotherapeutics
(NASDAQ:SABS)Latest News for SAB Biotherapeutics Stock (NASDAQ:SABS)
SAB Biotherapeutics Stock (NASDAQ: SABS)
Categories: All
Tuesday, April 16, 2024
- HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $6 Price TargetBenzinga Newsdesk - Apr 16, 2024, 1:28PM
- Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price TargetBenzinga Newsdesk - Apr 16, 2024, 7:41AM
- SAB Biotherapeutics' Has Completed Dosing The Third Cohort For Phase 1 Study Of SAB-142 In Healthy Volunteers And Participants With Type 1 Diabetes With No Observation Of Serum Sickness Thus FarBenzinga Newsdesk - Apr 16, 2024, 7:17AM
Tuesday, April 02, 2024
Monday, March 25, 2024
Friday, February 02, 2024
Tuesday, January 23, 2024
Monday, January 08, 2024
Friday, January 05, 2024
Thursday, January 04, 2024
Wednesday, January 03, 2024
Tuesday, January 02, 2024
Monday, December 04, 2023
Friday, December 01, 2023
Wednesday, November 29, 2023
- EXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In AustraliaVandana Singh - Nov 29, 2023, 7:00AM
- EXCLUSIVE: SAB Biotherapeutics Tells Benzinga 'SAB Biotherapeutics is pursuing IND and CTA filings with U.S. FDA and EMA in 2024 to clinically advance development of SAB-142 into Phase 2b study'Benzinga Newsdesk - Nov 29, 2023, 7:00AM
- EXCLUSIVE: SAB Biotherapeutics Tells Benzinga 'First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG)'Benzinga Newsdesk - Nov 29, 2023, 7:00AM
- EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Announces Commencement Of The HUMAN Phase I Clinical Trial With SAB-142, A Potential Disease-Modifying Treatment For Type 1 DiabetesBenzinga Newsdesk - Nov 29, 2023, 7:00AM
Thursday, November 16, 2023
Tuesday, November 14, 2023
Tuesday, October 24, 2023
Thursday, October 19, 2023
- Nasdaq Falls 100 Points; AT&T Posts Upbeat EarningsLisa Levin - Oct 19, 2023, 2:37PM
- Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Oct 19, 2023, 1:52PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Oct 19, 2023, 1:31PM
- SAB Biotherapeutics shares are trading higher after the company announced it received Australian approval to commence the Phase 1 clinical trial of SAB-142.Benzinga Newsdesk - Oct 19, 2023, 11:58AM
- Reported Earlier, SAB Biotherapeutics Receives Australian Approval To Commence Phase 1 Clinical Trial Of SAB-142, A Potential Disease-Modifying Treatment For Type 1 DiabetesBenzinga Newsdesk - Oct 19, 2023, 11:38AM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Oct 19, 2023, 9:06AM
Thursday, October 05, 2023
Monday, October 02, 2023
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Oct 2, 2023, 9:05AM
- EXCLUSIVE: SAB Biotherapeutics Tells Benzinga 'Financing led by RA Capital Management, with participation from BVF Partners, Sessa Capital, Commodore Capital, RTW Investments, Marshall Wace, and the JDRF T1D Fund'Benzinga Newsdesk - Oct 2, 2023, 7:15AM
- EXCLUSIVE: SAB Biotherapeutics Tells Benzinga 'Funding to support clinical advancement of SAB-142, a potential disease-modifying treatment'Benzinga Newsdesk - Oct 2, 2023, 7:15AM
- EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co Announces Private Placement Of Up To $130M To Advance Development Of Lead Drug Candidate For Type 1 DiabetesBenzinga Newsdesk - Oct 2, 2023, 7:15AM
- EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes CandidateVandana Singh - Oct 2, 2023, 7:15AM
Friday, September 29, 2023
Monday, August 28, 2023
Monday, August 21, 2023
Friday, August 11, 2023
Wednesday, June 21, 2023
- HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $4 Price TargetBenzinga Newsdesk - Jun 21, 2023, 11:46AM
- EXCLUSIVE: SAB Biotherapeutics Says Diabetes Immunotherapy Shows Therapeutic Effect In Toxicology StudyVandana Singh - Jun 21, 2023, 8:00AM
- EXCLUSIVE: SAB Biotherapeutics Tells Benzinga 'Study shows SAB's fully-human multi-target immune modulating therapeutic for treatment of Type 1 Diabetes is well tolerated'Benzinga Newsdesk - Jun 21, 2023, 8:00AM
- EXCLUSIVE: SAB Biotherapeutics Announces To Benzinga Presentation Of Safety And Pharmacologic Data From A GLP Toxicology Study For SAB-142Benzinga Newsdesk - Jun 21, 2023, 7:59AM